Treatment with Combination of Mithramycin A and Tolfenamic Acid Promotes Degradation of Sp1 Protein and Synergistic Antitumor Activity in Pancreatic Cancer

Previous studies showed that both mithramycin (MIT) and tolfenamic acid (TA) inhibits the activity of the transcription factor Sp1. In the present study, we sought to determine whether treatment with a combination of these two compounds has a synergistic effect on Sp1 activity and pancreatic cancer...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Jia, Zhiliang, Gao, Yong, Wang, Liwei, Li, Qiang, Zhang, Jun, Le, Xiangdong, Wei, Daoyan, Yao, James C., Chang, David Z., Huang, Suyun, Xie, Keping
Format: Artigo
Idioma:Inglês
Publicat: 2010
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2840649/
https://ncbi.nlm.nih.gov/pubmed/20086170
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-09-3282
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars